Colossal Biosciences is working to bring back species like the woolly mammoth using CRISPR-Cas9 technology. The project aims to restore lost biodivers ...

Fintel reports that on January 27, 2025, Morgan Stanley downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 449.14% ...

This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...

The early stage company is developing a new approach to gene editing to treat rare genetic diseases. It does this using mRNA, ...

Intellia Therapeutics has dosed the first subject in the Phase III trial of NTLA-2002, to treat hereditary angioedema (HAE).

New study reveals that TLE6 protein deficiency causes male infertility in mice. These findings suggest potential genetic ...

Associate Professor Qing Zhong shared insights on AI breakthroughs in proteomics and multiomics, challenges in data sharing ...

Scientists studying an aggressive cancer that affects thousands of dogs annually have uncovered a genetic signature that ...

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...

Colossal Biosciences is now valued at over $10 billion and is working on ambitious projects to resurrect multiple long ...

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...